MetroHealth has completed construction on a facility for the development of cancer therapies derived from a patient’s own immune cells. The A new lab is designed to speed and improve cancer treatment.
facility for the development of cancer therapies derived from a patient’s own immune cells.
In both of these therapies a patient’s own immune cells are collected, modified in the laboratory to recognize cancer cells, and then returned to the patient. CAR-T is primarily effective for certain blood-based cancers, while TIL is being developed for certain types of solid tumors. The benefits of hospital-based lab capabilities have led a number of systems to invest in their own laboratories.recently spent $10 million
Currently, even centers that are producing their own CAR-T cells still rely on commercially available products called vectors to “educate” the cells against cancer. These commercial products are the building blocks of all cellular therapies, and they are in extremely short supply, explained MetroHealth Service Line Administrator for Cancer CareTheir lack of availability creates a bottleneck that impedes a lab’s ability to produce clinical treatments in a timely manner.
“What we’re doing here at MetroHealth is investing in something that can help fuel the discovery of more of these CAR-T’s ... and at the same time we will also have the ability to build those CAR-T cells, so we can take our own input and say hey collaborator in Boston, or collaborator in New York, or anywhere, you have a CAR-T product that you want to develop? we’ll do it from beginning to end,” said Kovach.
Although cell-based immune therapies like CAR-T received FDA approval several years ago, the field as a whole is still rather new, and rapidly changing. This type of leading-edge research is most often offered at large centers of academic research, rather than public hospitals.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
MetroHealth CEO Airica Steed ‘full steam ahead’ on $1B ‘hospital-in-a-park’ vision as she conducts due diligence on plansMetroHealth’s new president and CEO, Airica Steed, said Tuesday that she needs to conduct her own due diligence to make sure the $1 billion campus transformation plans are up-to-date with MetroHealth’s current needs.
Consulte Mais informação »
Aspirin: New insights on the 'magic drug' could help cancer patientsScientists discovered new information about how aspirin works in the body. These new insights are valuable as they could lead to better cancer therapies.
Consulte Mais informação »
Bacterial ‘Syringe’ Could Lead to Brand New Cancer TherapiesNo needles required.
Consulte Mais informação »
Cancer blood test may 'prey on the worried well'An oncologist questions the benefit of a firm charging more than £1,000 for a new cancer cell test.
Consulte Mais informação »
Ornithine aminotransferase supports polyamine synthesis in pancreatic cancer - NaturePancreatic ductal adenocarcinoma cells show a specific dependency on ornithine aminotransferase-mediated ornithine synthesis from glutamine, providing an opportunity to develop targeted therapies with minimal toxicity for this cancer.
Consulte Mais informação »
MetroHealth CEO Airica Steed ‘full steam ahead’ on $1B ‘hospital-in-a-park’ vision as she conducts due diligence on plansMetroHealth’s new president and CEO, Airica Steed, said Tuesday that she needs to conduct her own due diligence to make sure the $1 billion campus transformation plans are up-to-date with MetroHealth’s current needs.
Consulte Mais informação »